Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial

[1]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[2]  S. Culine,et al.  Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[4]  D. Stenehjem,et al.  PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer , 2018, OncoTargets and therapy.

[5]  N. Shinohara,et al.  Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan , 2018, Japanese journal of clinical oncology.

[6]  K. Kuratsukuri,et al.  Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma , 2018, International Journal of Clinical Oncology.

[7]  S. Culine,et al.  Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Urakami,et al.  Recent advances in medical therapy for metastatic urothelial cancer , 2018, International Journal of Clinical Oncology.

[9]  Nicholas J. Vogelzang,et al.  Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study , 2017, JAMA oncology.

[10]  A. Ravaud,et al.  Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Plimack,et al.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.

[12]  R. Machii,et al.  Incidence rate for prostate cancer in Japanese in Japan and in the United States from the Cancer Incidence in Five Continents. , 2017, Japanese Journal of Clinical Oncology.

[13]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[14]  N. Shinohara,et al.  Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan. , 2017, Urologic oncology.

[15]  J. Lunceford,et al.  Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. , 2017, The Lancet. Oncology.

[16]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[17]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[18]  Yoshiaki Yamamoto,et al.  Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy. , 2016, Japanese journal of clinical oncology.

[19]  S. Tsugane,et al.  Cancer in Japan: Prevalence, prevention and the role of heterocyclic amines in human carcinogenesis , 2016, Genes and Environment.

[20]  Y. Kubota,et al.  Essential content of evidence‐based clinical practice guidelines for bladder cancer: The Japanese Urological Association 2015 update , 2016, International journal of urology : official journal of the Japanese Urological Association.

[21]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[22]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[23]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[24]  G. Pond,et al.  Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. , 2013, European urology.

[25]  R. Sylvester,et al.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Culine,et al.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  H. Nishiyama.  Asia Consensus Statement on NCCN Clinical Practice Guideline for bladder cancer , 2018, Japanese journal of clinical oncology.

[28]  T. Matsuda,et al.  Incidence rate for bladder cancer in Japanese in Japan and in the United States from the Cancer Incidence in Five Continents. , 2017, Japanese journal of clinical oncology.

[29]  H. Akaza.  Urologic cancer in Japan: role of Japan at the frontier of issues in Asia. , 2016, Japanese journal of clinical oncology.

[30]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[31]  J. Richie,et al.  Bladder cancer. Clinical practice guidelines in oncology. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.